The Thorne deal is Procter & Gamble buying a private-equity trade near its top, and the trust that made Thorne worth 5.6x is the one thing P&G’s machine is worst at protecting.
Procter & Gamble is buying supplement brand Thorne for $3.8 billion. L Catterton took Thorne private three years ago for $680 million. That is roughly a 5.6x step-up in about 36 months, and most of it came from a fatter multiple, not just faster growth. What P&G actually bought is a high-trust, athlete-certified, direct-to-consumer engine. What P&G is famous for is the opposite: mass shelves and cost-down. That gap is the whole story.
Every outlet is running the same headline this morning: big consumer-goods giant buys hot wellness brand, demographics are great, next. That frame is true and boring. The interesting version starts with the price tag and asks a sharper question: what did P&G think it was paying for, and can it keep that thing alive once Thorne is inside a 188-year-old detergent-and-diapers conglomerate?
What Happened
P&G agreed to acquire Thorne for $3.8 billion, CEO Shailesh Jejurikar told CNBC on Tuesday, framing it as a bigger push into beauty and health. He called Thorne “a really well-run operation” and said the company likes an area where it feels the demographics are on its side.
Thorne sells creatine, prenatal vitamins, hormone-support products and at-home health testing, wrapped in a personalization layer. It is NSF Certified for Sport, the official supplement of the UFC, and a supplier to pro athletes across several sports. Founded in 1984, it went public in late 2021 at a $525 million valuation, then got taken private by L Catterton in 2023.
The brand slots into a healthcare division at P&G that already holds Metamucil, Align Probiotic and New Chapter vitamins, alongside Oral-B and Vicks. So P&G is not new to the supplement aisle. It is new to this kind of supplement brand.
The Backstory
Here is the context the deal note leaves out. P&G’s own growth engine has run out of road.
The company closed fiscal 2026 with about $87 billion in net sales, up 3%, but nearly all of that came from foreign exchange and price increases. Volume and mix contributed essentially nothing across the year, and in the June quarter organic sales were flat on every lever. For four years, pricing did the heavy lifting at P&G, and that lever has now stopped moving. Management is guiding to an earnings drag from higher input costs in fiscal 2027.
When your core categories stop growing in volume and you can no longer raise prices, you buy growth. Thorne compounds revenue north of 30% a year. That is not a bolt-on; that is a transfusion.
Meanwhile, the seller ran a clinic. L Catterton, the LVMH-linked consumer investor, bought Thorne in the middle of a dead 2023 M&A market, then more than doubled revenue from roughly $229 million in 2022 to over $500 million in 2025, with the business on pace for about $650 million this year. Direct customers grew from around 4 million at the end of 2023 to about 7 million, a 63% surge in direct-to-consumer sales. Buy a good asset cheap when nobody is bidding, grow it, sell it hot to a strategic that has to have it. Textbook.
The Plan
P&G’s stated plan is to build a bigger beauty-and-wellness portfolio aimed at a demographic it likes. Read the “demographics” line carefully, because it is where most coverage will go wrong.
The instinct is to picture aging boomers and a pill organizer. Thorne’s growth is the opposite. It has been powered by Gen Z and millennial shoppers, the healthspan-and-optimization crowd who treat creatine, protein and hormone support as a daily identity, not a prescription. P&G is not buying the geriatric vitamin aisle. It is buying youth wellness culture, and the recurring, high-frequency, subscription-shaped revenue that comes with it.
That also explains the price. P&G is not paying a detergent multiple. It is paying a premium-brand, DTC-relationship multiple.
The Business Model Angle
Strip the wellness language away and the deal is a bet on a number: the multiple.
L Catterton entered at roughly 2.4x revenue. P&G is exiting them at something closer to 6x forward revenue, or about 7.6x on last year’s $500 million-plus. Revenue itself grew maybe 2.3x over the hold. The rest of the 5.6x came from multiple expansion: the market decided a fast-growing, DTC-native supplement brand is simply worth more revenue-for-revenue than it was in 2023.
Why would a mass-market operator pay up like that? Because the expensive part is not the creatine. It is the customer relationship. Thorne owns roughly 7 million direct consumers, a certification stack that pro sports leagues actually trust, and a testing-and-personalization data loop that keeps people subscribed. That is a customer-acquisition-and-retention machine P&G cannot build organically, and it just watched a rival prove the market rate.
That rival is Unilever, which paid an estimated $1.2 billion for gummy brand Grüns in April, roughly 4x revenue on a company barely three years old. Unilever already owns Olly, SmartyPants, Nutrafol and Liquid I.V. Add P&G and Thorne, and you have a clear pattern: the biggest consumer-goods incumbents are paying trust-brand multiples for DTC supplement engines because their own purpose-led, shelf-first models cannot manufacture that kind of community from scratch. They are buying the relationship and skipping five years of trial and error.
The Risk
Here is the tension nobody is pricing on announcement day, and it is not “P&G overpaid.” At 30%-plus growth with a real retention moat, roughly 6x forward revenue is defensible. The risk is operational.
P&G’s entire model rests on one assumption: shoppers will pay a premium over the store brand because the product is measurably superior, distributed everywhere, and merchandised hard. That works beautifully for a razor or a detergent. It is a strange fit for a brand whose premium comes from feeling clinical, discerning and slightly exclusive, sold heavily direct rather than stacked in an endcap.
So the integration fork is real. Scale it right, and P&G’s distribution muscle can put Thorne into far more hands without cheapening it. Scale it wrong, and P&G does what big CPG often does to a premium acquisition: widens distribution, chases volume, trims the practitioner and athlete positioning that justified the trust in the first place, and slowly turns a $3.8 billion trust asset into another Metamucil. The thing that made Thorne worth 5.6x is the exact thing the acquirer’s DNA pushes against.
P&G has integrated a marquee brand before. It bought Gillette for $57 billion in 2005 and kept it a category leader. But Gillette was a mass shaving brand being absorbed by a mass operator. Thorne is a trust-and-community brand being absorbed by a mass operator. Different problem entirely.
Quick Questions
How much did L Catterton make? Roughly a 5.6x on the equity value: $680 million in, $3.8 billion out, in about three years. Growth doubled the base; multiple expansion did most of the rest.
Is $3.8 billion an overpay? Not obviously. It pencils to about 6x forward revenue on a business growing 30%-plus with strong DTC retention. Unilever paid about 4x for the far younger Grüns. The real question is operational, not valuation.
What does P&G actually get? About 7 million direct customers, a sports-certification and testing moat, a 30%-plus growth line, and immediate scale in a category where its own volume growth has stalled.
Why now? Because P&G’s core is out of organic growth. Price and FX carried fiscal 2026; volume did not. Buying a 30% grower is faster than reviving a flat one.
Who is next? Any independent, DTC-heavy, science-forward supplement brand with real retention. The incumbents are actively shopping, and each deal resets the going multiple higher.
The Business Model Analyst Take
The clean way to read this deal: P&G did not buy a vitamin company, it bought L Catterton’s multiple-arbitrage trade near the top, plus a growth line it can no longer generate at home.
That is a smart, even necessary move for a company whose pricing engine has flatlined. But the value it just paid for lives in the softest place on a balance sheet: trust, community and a direct relationship with 7 million people who believe Thorne is different. P&G’s superpower is making the same product cheaper and putting it everywhere. Applied carelessly, that superpower is exactly how you erode a premium wellness brand.
The deal will be judged not on the $3.8 billion, which is fine, but on whether P&G has the discipline to leave the thing it bought mostly alone. Big CPG is not historically famous for that discipline. Watch the distribution strategy and the certification positioning over the next 18 months. If Thorne stays discerning, this looks brilliant in hindsight. If it shows up three-for-$40 in every drugstore, P&G will have paid trust-brand money to manufacture a commodity.
